CRISPR’s (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
ZacksCRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.